---
title: "China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305757945.md"
description: "China's NMPA has accepted Akeso's application for ivonescimab combined with chemotherapy as a first-line treatment for locally advanced or metastatic biliary tract cancer. The application previously received priority review designation. Clinical data from Phase III trials showed a median overall survival of 14.9 months with ivonescimab compared to 12.1 months with durvalumab, both in combination with chemotherapy."
datetime: "2026-11-17T03:31:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305757945.md)
  - [en](https://longbridge.com/en/news/305757945.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305757945.md)
generator: "portal-rs"
---

# China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer

-   China’s NMPA accepted Akeso’s application for ivonescimab with chemotherapy as first-line treatment for locally advanced or metastatic biliary tract cancer. \* The application previously received priority review designation. \* Phase III median overall survival reached 14.9 months with ivonescimab versus 12.1 months with durvalumab, both combined with chemotherapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611162230PR\_NEWS\_USPR\_\_\_\_\_CN99665) on November 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [Akeso's Ivonescimab Gets China Priority Review for First-Line Biliary Tract Cancer](https://longbridge.com/en/news/304383552.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**